Why Advanced Micro Devices fueled Kodiak Sciences stock up 180%

Biotechnology firm Kodiak Sciences (KOD) saw its shares surge more than 170% on Monday following encouraging outcomes from its wet age-related macular degeneration (AMD) clinical trials. After concluding the Phase 3 DAYBREAK study for wet AMD and sharing its major findings, the stock jumped from a previous close in the low $30s to end Monday near $87. The following day, the stock experienced a modest correction of about 3% downward.

The company revealed that its two investigational wet AMD therapies, Zenkuda and KSI-501, successfully achieved their primary objectives in the late-stage trial. Specifically, Zenkuda showed signs of establishing “a potential new standard-of-care profile” by providing immediate post-administration relief combined with extended therapeutic efficacy.

These stock increases mirror the rising market value of tech firms such as Advanced Micro Devices (AMD). Both equities advanced on Monday, bringing KOD’s total gains for the year to 15%. Kodiak Sciences estimates the worldwide market for retinal vascular disease medications at $15 billion, positioning itself to capture a portion of this competitive sector—following the late-July regulatory approval of Outlook Therapeutics’ Lytenava for wet AMD.

Building on these clinical outcomes, Kodiak Sciences intends to submit a Biologics License Application for Zenkuda in the fourth quarter to formally request marketing approval. Should this application succeed, Zenkuda will transition from being a long-standing development pipeline asset into Kodiak Sciences’ inaugural commercial product.

KOD has now transformed into a catalyst-driven battleground. UBS has issued a Buy rating alongside an $80 price target for Kodiak Sciences, suggesting that the Phase III wet AMD evaluations for tarcocimab and KSI-501 will likely prove non-inferior to Eylea, the established standard therapy. The key differentiator is dosing frequency. If Kodiak’s medications successfully extend the time between treatments, the commercial perspective evolves from a standard alternative to a significantly more convenient choice, paving the way for premium pricing and widespread patient adoption.

Frequently Asked Questions

Why did Kodiak Sciences stock surge?

Shares jumped over 170% on Monday following positive results from the Phase 3 DAYBREAK study for wet AMD, where experimental treatments Zenkuda and KSI-501 met their primary goals.

What are Zenkuda and KSI-501?

They are two experimental treatments developed by Kodiak Sciences for wet age-related macular degeneration (AMD).

What is the next regulatory step for Zenkuda?

Kodiak Sciences plans to submit a Biologics License Application for Zenkuda in the fourth quarter to seek formal marketing approval.

What is the estimated size of the retinal vascular disease drug market?

According to Kodiak Sciences, the global market for these drugs is valued at $15 billion.

What financial rating and price target did UBS assign to KOD?

UBS has given Kodiak Sciences a Buy rating with an $80 price target.